Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from HeraMED Ltd. ( (AU:HMD) ).
HeraMED has released an investor presentation outlining its position as a leader in AI-enabled women’s health, leveraging an FDA-cleared device to deliver solutions from pregnancy through to chronic care. The update is intended to inform investors about the company’s strategic focus on proprietary technology and data-driven care models, which aim to strengthen its market positioning in the growing digital and remote healthcare sector while underlining its ambition to scale within women’s health services.
The most recent analyst rating on (AU:HMD) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on HeraMED Ltd. stock, see the AU:HMD Stock Forecast page.
More about HeraMED Ltd.
HeraMED Ltd. is an Australian-based digital health company focused on AI-powered women’s health solutions. The company offers technology that spans pregnancy monitoring to chronic care management, built around a proprietary, FDA-cleared medical device that underpins its remote care and data-driven service offerings.
Average Trading Volume: 758,206
Technical Sentiment Signal: Buy
Current Market Cap: A$41.21M
See more data about HMD stock on TipRanks’ Stock Analysis page.